Andrea Marta Escalante

Dr. Andrea Marta Escalante

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2016 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
AOA. Gastón Orrillo
A. Gastón Orrillo
Andrea Marta EscalanteAndrea Marta Escalante
Andrea Marta Escalante
RFRicardo L.E. Furlan
Ricardo L.E. Furlan

19 September 2018 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
AOA. Gastón Orrillo
A. Gastón Orrillo
Andrea Marta EscalanteAndrea Marta Escalante
Andrea Marta Escalante
MMMaitena Martinez‐Amezaga
Maitena Martinez‐Amezaga
ICIgnacio Cabezudo
Ignacio Cabezudo
RFRicardo L.E. Furlan
Ricardo L.E. Furlan
Dynamic multilevel systems can be assembled from molecular building blocks through two or more reversible reactions that form covalent bonds. Molecular networks of dynamic multilevel systems can exhibit different connectivities between nodes. The design and creation of molecular networks in multilevel systems require control of the crossed reactivity of the functional groups (how to connect nodes) and the conditions of the reactions (when to connect nodes). In recent years, the combination of orthogonal and communicating reactions, which can be simultaneous or individually activated, has produced a variety of systems that have given rise to macrocycles and cages, as well as molecular motors and multicomponent architectures on surfaces. A given set of reactions can lead to systems with unique responsiveness, compositions, and functions as a result of the relative reactivities. In this Concept article, different molecular networks from synthetic systems that can be produced by combinations of different reaction types are discussed. Moreover, applications of this chemistry are highlighted, and future perspectives are envisioned.

5 February 2018 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
AOA. Gastón Orrillo
A. Gastón Orrillo
ALAgustina La-Venia
Agustina La-Venia
Andrea Marta EscalanteAndrea Marta Escalante
Andrea Marta Escalante
RFRicardo L.E. Furlan
Ricardo L.E. Furlan

11 September 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PGPaula García
Paula García
VAVictoria Lucia Alonso
Victoria Lucia Alonso
ESEsteban Serra
Esteban Serra
Andrea Marta EscalanteAndrea Marta Escalante
Andrea Marta Escalante
RFRicardo L.E. Furlan
Ricardo L.E. Furlan

1 October 2024 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
VAVictoria L. Alonso
Victoria L. Alonso
Andrea Marta EscalanteAndrea Marta Escalante
Andrea Marta Escalante
EAElvio Rodríguez Araya
Elvio Rodríguez Araya
GFGianfranco Frattini
Gianfranco Frattini
LTLuis E. Tavernelli
Luis E. Tavernelli
SSSerra Serra
Serra Serra
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects millions globally, with increasing urban cases outside of Latin America. Treatment is based on two compounds, namely, benznidazole (BZ) and nifurtimox, but chronic cases pose several challenges. Targeting lysine acetylation, particularly bromodomain-containing proteins, shows promise as a novel antiparasitic target. Our research focuses on TcBDF3, a cytoplasmic protein, which is crucial for parasite differentiation that recognizes acetylated alpha-tubulin. In our previous study, A1B4 was identified as a high-affinity binder of TcBDF3, showing significant trypanocidal activity with low host toxicity in vitro. In this report, the binding of TcBDF3 to A1B4 was validated using differential scanning fluorescence, fluorescence polarization, and molecular modeling, confirming its specific interaction. Additionally, two new 1,3,4-oxadiazoles derived from A1B4 were identified, which exhibited improved trypanocide activity and cytotoxicity profiles. Furthermore, TcBDF3 was classified for the first time as an atypical divergent member of the bromodomain extraterminal family found in protists and plants. These results make TcBDF3 a unique target due to its localization and known functions not shared with higher eukaryotes, which holds promise for Chagas disease treatment.

1 January 2022 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
RRRosana Rotondo
Rosana Rotondo
PCPablo Santa Cruz
Pablo Santa Cruz
MMMarianela Masin
Marianela Masin
MBMilagros Bürgi
Milagros Bürgi
JGJavier Girardini
Javier Girardini
Andrea Marta EscalanteAndrea Marta Escalante
Andrea Marta Escalante